CP 42,096
  • (6aR,9R,10aR)-6,6-dimethyl-3-(5-phenylpentan-2-yloxy)-6a,7,8,9,10,10a-hexahydrobenzo[c]chromene-1,9-diol
PubChem CID
Chemical and physical data
Molar mass410.554 g·mol−1
3D model (JSmol)
  • CC(CCCC1=CC=CC=C1)OC2=CC(=C3[C@@H]4C[C@@H](CC[C@H]4C(OC3=C2)(C)C)O)O
  • InChI=1S/C26H34O4/c1-17(8-7-11-18-9-5-4-6-10-18)29-20-15-23(28)25-21-14-19(27)12-13-22(21)26(2,3)30-24(25)16-20/h4-6,9-10,15-17,19,21-22,27-28H,7-8,11-14H2,1-3H3/t17?,19-,21-,22-/m1/s1

CP 42,096 is an analgesic drug which acts as a cannabinoid agonist. It was developed by Pfizer in the 1980s as part of the research that led to the development of levonantradol,[1][2][3] and is more potent than THC but less potent than newer compounds such as CP 55,244.[4][5]

See also


  1. ^ Howlett AC, Johnson MR, Melvin LS, Milne GM (March 1988). "Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model". Molecular Pharmacology. 33 (3): 297–302. PMID 3352594.
  2. ^ Prescott WR, Martin BR (1990). "The evaluation of synthetic cannabimimetic congeners for discriminative stimulus and cataleptogenic effects in rats". NIDA Research Monograph. 105: 421. OCLC 7457082. PMID 1652087.
  3. ^ Koe BK (1999). "Levonantradol". In Nahas GG, Sutin KM, Harvey D, Agurell S, Pace N, Cancro R (eds.). Marihuana and Medicine. Totowa, NJ: Humana Press. pp. 553–560. doi:10.1007/978-1-59259-710-9_53. ISBN 978-1-4757-5717-0.
  4. ^ Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS (February 1985). "Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics". European Journal of Pharmacology. 109 (2): 201–12. doi:10.1016/0014-2999(85)90421-2. PMID 2986995.
  5. ^ "Hexahydrocannabinol (HHC) and related substances" (PDF). European Monitoring Centre for Drugs and Drug Addiction. 2023.